GenePlanet, a Slovenian genomics and laboratory services company, has secured a strategic investment from Lauxera Capital Partners, a healthtech-focused investment firm. The funding round marks a significant milestone for the growing European genomics player and reflects continued investor confidence in the genetic testing and sequencing market.
The investment structure saw early-stage supporter BlackPeak Capital partially exit its position in the company, though the firm will maintain a stake on the capitalization table. This arrangement demonstrates the gradual transition typical of maturing companies as new strategic investors join the shareholder base.
Expanding European Genomics Services
GenePlanet operates in the rapidly evolving healthtech and genomics sector, offering genetic testing and next-generation sequencing services to customers across Europe. The company’s service portfolio positions it within a broader market segment addressing growing demand for personalized medicine and genetic diagnostics on the continent.
The strategic nature of Lauxera Capital Partners’ investment suggests the firm sees particular value in GenePlanet’s existing operations and European market positioning. Lauxera’s focus on healthtech investments aligns with GenePlanet’s core business, indicating the investor brings sector expertise and strategic connections to support the company’s growth trajectory.
Supporting Growth Across the Region
The fresh capital injection provides GenePlanet with resources to expand its genetic testing and sequencing capabilities across European markets. Companies operating in genomics and diagnostic testing face increasing opportunities as healthcare systems modernize their diagnostic infrastructure and patients gain greater access to personalized health insights.
BlackPeak Capital’s decision to partially exit rather than fully divest suggests confidence in the company’s trajectory, while allowing the early investor to realize returns on its initial backing. This phased exit approach has become increasingly common among venture investors managing diverse portfolios across the European tech landscape.
European Genomics Market Dynamics
GenePlanet’s funding round reflects broader trends within the European startup ecosystem, where genomics and personalized medicine companies continue attracting investment from both generalist venture firms and specialized healthtech investors. The continent has developed a growing network of genomics-focused startups, particularly across Central and Eastern European hubs.
The strategic investment model pursued by Lauxera Capital Partners mirrors a wider shift toward more specialized, sector-focused funding approaches in European venture capital. Rather than generic growth capital, companies increasingly attract investors with deep domain expertise and networks within their specific verticals.
As European healthcare systems continue prioritizing precision medicine and diagnostic innovation, companies offering genetic testing and sequencing services occupy an increasingly central position in the broader healthtech ecosystem. GenePlanet’s expansion with Lauxera’s backing illustrates how Slovenian founders are building significant regional players in this critical healthcare infrastructure space.